The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.

TitleThe Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.
Publication TypeJournal Article
Year of Publication2017
AuthorsPardo, F., Sangro B., Lee R-C., Manas D., Jeyarajah R., Donckier V., Maleux G., Pinna A. D., Bester L., Morris D. L., Iannitti D., Chow P. K., Stubbs R., Gow P. J., Masi G., Fisher K. T., Lau W. Y., Kouladouros K., Katsanos G., Ercolani G., Rotellar F., Bilbao J. I., & Schoen M.
JournalAnn Surg Oncol
Volume24
Issue9
Pagination2465-2473
Date Published2017 Sep
ISSN1534-4681
KeywordsAged, Brachytherapy, Female, Hepatectomy, Humans, Liver Failure, Liver Neoplasms, Liver Transplantation, Male, Microspheres, Middle Aged, Postoperative Complications, Radiotherapy, Adjuvant, Retrospective Studies, Yttrium Radioisotopes
Abstract

BACKGROUND: Reports show that selective internal radiation therapy (SIRT) may downsize inoperable liver tumors to resection or transplantation, or enable a bridge-to-transplant. A small-cohort study found that long-term survival in patients undergoing resection following SIRT appears possible but no robust studies on postsurgical safety outcomes exist. The Post-SIR-Spheres Surgery Study was an international, multicenter, retrospective study to assess safety outcomes of liver resection or transplantation following SIRT with yttrium-90 (Y-90) resin microspheres (SIR-Spheres; Sirtex).
METHODS: Data were captured retrospectively at participating SIRT centers, with Y-90 resin microspheres, surgery (resection or transplantation), and follow-up for all eligible patients. Primary endpoints were perioperative and 90-day postoperative morbidity and mortality. Standard statistical methods were used.
RESULTS: The study included 100 patients [hepatocellular carcinoma: 49; metastatic colorectal cancer (mCRC): 30; cholangiocarcinoma, metastatic neuroendocrine tumor, other: 7 each]; 36% of patients had one or more lines of chemotherapy pre-SIRT. Sixty-three percent of patients had comorbidities, including hypertension (44%), diabetes (26%), and cardiopathy (16%). Post-SIRT, 71 patients were resected and 29 received a liver transplant. Grade 3+ peri/postoperative complications and any grade of liver failure were experienced by 24 and 7% of patients, respectively. Four patients died <90 days postsurgery; all were trisectionectomies (mCRC: 3; cholangiocarcinoma: 1) and typically had one or more previous chemotherapy lines and presurgical comorbidities.
CONCLUSIONS: In 100 patients undergoing liver surgery after receiving SIRT, mortality and complication rates appeared acceptable given the risk profile of the recruited patients.

DOI10.1245/s10434-017-5950-z
Alternate JournalAnn Surg Oncol
PubMed ID28653161

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.